Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · as published 2026-01-23 View official record Methodology

Covered recipient · General Payments record

LAKSHMAN RAO

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1063468809
CMS profile
184866
Location
ERWIN, NC

General Payments · PY2018–2024

$3,746.34

  • Reported across 266 records
  • CMS publication 2026-01-23

Latest program year · PY2024

$268.74

15 records · 0 disputed

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How these totals are calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

PY2024 · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $268.74 15

By paying entity

PY2024 · sorted by reported total

Paying entityAmountRecords
Novo Nordisk AS $76.59 4
GlaxoSmithKline, LLC. $41.03 2
Exact Sciences Corporation $37.35 2
Amgen Inc. $29.43 2
Nevro Corp. $20.50 1
Lilly USA, LLC $19.47 1
AIMMUNE THERAPEUTICS, INC. $17.10 1
Bayer HealthCare Pharmaceuticals Inc. $13.78 1
PFIZER INC. $13.49 1

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2018 $1,470.73 115
PY2019 $1,509.05 102
PY2020 $478.47 33
PY2021 $19.35 1
PY2024 $268.74 15

Payment records · PY2024 (15)

Sorted by paying entity, then date · as published by CMS

Program year 2024 2018201920202021 Record-level detail is published for PY2024; earlier years are summarised in “By program year”.
Paying entity Amount Date Nature of payment Dispute status Published Record ID Source
AIMMUNE THERAPEUTICS, INC. $17.10 11/06/2024 Food and Beverage Undisputed 01/23/2026 1147005055 CMS
Amgen Inc. $13.79 09/24/2024 Food and Beverage Undisputed 01/23/2026 1117360872 CMS
Amgen Inc. $15.64 11/20/2024 Food and Beverage Undisputed 01/23/2026 1117360874 CMS
Bayer Healthcare Pharmaceuticals Inc. $13.78 10/01/2024 Food and Beverage Undisputed 01/23/2026 1086187538 CMS
Exact Sciences Corporation $18.06 08/20/2024 Food and Beverage Undisputed 01/23/2026 1114847733 CMS
Exact Sciences Corporation $19.29 11/21/2024 Food and Beverage Undisputed 01/23/2026 1114847738 CMS
GlaxoSmithKline, LLC. $19.93 09/18/2024 Food and Beverage Undisputed 01/23/2026 1116612724 CMS
GlaxoSmithKline, LLC. $21.10 11/13/2024 Food and Beverage Undisputed 01/23/2026 1115886571 CMS
Lilly USA, LLC $19.47 10/14/2024 Food and Beverage Undisputed 01/23/2026 1135144511 CMS
Nevro Corp. $20.50 11/18/2024 Food and Beverage Undisputed 01/23/2026 1130762371 CMS
Novo Nordisk Inc $26.89 10/09/2024 Food and Beverage Undisputed 01/23/2026 1096961137 CMS
Novo Nordisk Inc $16.49 10/21/2024 Food and Beverage Undisputed 01/23/2026 1096910601 CMS
Novo Nordisk Inc $17.90 12/04/2024 Food and Beverage Undisputed 01/23/2026 1097118878 CMS
Novo Nordisk Inc $15.31 12/05/2024 Food and Beverage Undisputed 01/23/2026 1096937001 CMS
PFIZER INC. $13.49 10/15/2024 Food and Beverage Undisputed 01/23/2026 1132094988 CMS

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-01-23
Program years on this page
2018, 2019, 2020, 2021, 2024
Source files
Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.